Projects

Ing. Lucia Demková, PhD.

International

Finished
  • Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumors
    Program: ERANET
    Duration: 1. 9. 2019 – 31. 3. 2023
  • Role of IL-6/NF-κB /HIF-1 axis in adipose tissue mesenchymal stromal cells-mediated breast cancer cells stemness
    Program: Bilateral - other
    Duration: 1. 1. 2017 – 31. 12. 2018

National

Current
  • DNA methylation biomarkers as a tool for the implementation of liquid biopsy in uveal melanoma
    Program: VEGA
    Duration: 1. 1. 2024 – 31. 12. 2027
Finished
  • Suicide gene therapy mediated by mesenchymal stromal and pancreatic tumor cell-excreted extracellular vesicles in the treatment of pancreatic ductal adenocarcinoma
    Program: SRDA
    Duration: 1. 7. 2021 – 30. 6. 2025
  • Exosomes secreted by cancer cells of digestive organs, their characterization and modification by the CRISPR/Cas9 system for the aim of use in therapy
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Development of patients derived xenografts models and their utilization for personalized treatment of uveal melanoma
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Identification of chemoresistant cell populations with metastatic potential in colorectal carcinoma
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • Markers overlapping chemoresistance and metastatic potential in colorectal cancer - aldehyde dehydrogenase and its clinical relevance
    Program: Other projects
    Duration: 1. 11. 2019 – 31. 12. 2022
  • TArgetiNg Dna mEthylation by epigenetic editing and its implementation into personalised diagnostics and therapy of uveal Melanoma
    Program: SRDA
    Duration: 1. 8. 2018 – 31. 12. 2022
  • Identification and validation of signalling pathways associated with circulating tumor cells in breast cancer
    Program: SRDA
    Duration: 1. 7. 2017 – 30. 6. 2021
  • Cellular and molecular traits of human metastasis-initiating cells at different stages of metastasis development.
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • The role of ALDH1 in chemoresistance of cancer cells
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • Role of Stress Response Induced in Mesenchymal Stromal Cells in Extrinsic Drug Resistance of Human Tumor Cells
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Mechanisms of interactions and bystander effect mediated by mesenchymal stromal cells expressing prodrug-converting genes on tumour stem cells
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 9. 2017
  • Cytotoxic Effect of Engineered Mesenchymal Stromal Cells on Human Chemoresistant Tumour Cells and Cancer Stem Cells
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • Reversion of chemoresistance of human cancer stem cells
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • Targeted Augmented Cellular Therapy against Tumor Initiating and Chemoresistant Cells
    Program: SRDA
    Duration: 1. 7. 2012 – 31. 12. 2015
  • Molecular mechanisms of tumor-driven mesenchymal stromal cells‘ differentiation
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2014
Employees